Citizen Petition from Nicholas W. Brown, Attorney General of Washington, et. al.

The Emergency Medicine Residents’ Association (EMRA) expresses full support for several citizen petitions requesting that the FDA remove the Mifepristone Shared System Risk Evaluation and Mitigation Strategy (REMS) or, at minimum, refrain from actions that would reduce patient access to the drug. The organization represents over 19,000 emergency medicine residents and medical students.

Physicians for Reproductive Health, a physician-led national advocacy organization, supports the citizen petitions seeking to eliminate current restrictions on mifepristone access. They argue that mifepristone is safe and effective for medication abortion and miscarriage management, and that current restrictions—particularly those requiring in-person dispensing—unnecessarily create barriers to care and harm the patient-provider relationship.

The Boston University School of Law, through several of its legal programs, supports the petition to eliminate the Mifepristone Shared System Risk Evaluation and Mitigation Strategy (REMS) or, at minimum, refrain from imposing additional restrictions on it. They argue that restricting access to mifepristone increases intimate partner violence (IPV) and imposes significant social and economic burdens, particularly on marginalized and low-income communities.

Legal Voice, Family Violence Appellate Project, Sexual Violence Law Center, and the Washington State Coalition Against Domestic Violence are submitting a joint comment in support of the petition to remove or relax restrictions on mifepristone. They argue that maintaining these requirements creates significant barriers to healthcare, particularly for survivors of intimate partner violence and marginalized communities who rely on private, telehealth-based medication abortion.

The UCLA Law Center for Reproductive Health, Law, and Policy and UCSF Advancing New Standards in Reproductive Health, representing 263 reproductive health researchers, submit this comment in support of citizen petitions asking the FDA to refrain from imposing additional restrictions on mifepristone. They argue that decades of gold-standard science confirm the safety and effectiveness of mifepristone, including via telehealth, and contend that recent reports by the Ethics and Public Policy Center are methodologically flawed and lack transparency.

Jamie Phifer, M.D., representing Abortion On Demand (a physician-owned LLC), supports the citizen petitions requesting that the FDA eliminate restrictions on mifepristone access. The commenter argues that their telehealth model provides safe, convenient, and timely medication abortion care, particularly for rural and low-income patients who face significant barriers to in-person care.

Hey Jane, a telehealth reproductive healthcare provider, submits this comment in support of the citizen petitions. The company argues that mifepristone access via telehealth is safe, effective, and vital for patients, and they request that the FDA eliminate current restrictions on its access.

The Reproductive Health Outcomes and Disparities (RHOADs) Research Lab at the University of Chicago supports the petition to remove the mifepristone REMS or, at minimum, prevent actions that reduce patient access. They argue that mifepristone is safe and effective, and that current and proposed regulations create significant administrative and logistical barriers that negatively impact maternal health, socioeconomic stability, and child well-being.